Trugman 1988.

Methods	A patient report of cerebral arteritis during methylphenidate treatment
Participants	Diagnosis of ADHD: ICD‐9 (unspecified hyperkinetic syndrome) Age: 12 years old IQ: not stated Sex: male Ethnicity: not stated Country: USA Comorbidity: not stated Comedication: not stated Sociodemographics: not stated
Interventions	Methylphenidate type: not stated Methylphenidate dosage: 10 mg Administration schedule: twice daily Duration of treatment: 5‐12 years of age (7 years) Treatment compliance: not stated
Outcomes	Serious adverse events: Right hemiparesis, 7 years following daily consumption of methylphenidate Aphasia Non‐serious adverse events: Headaches, intermittently before onset of stroke
Notes	Key conclusions of the study authors: cerebral arteritis and infarction were caused by chronic oral methylphenidate use. The CSF profile and angiogram support the diagnosis of inflammatory arteritis, yet laboratory evaluation revealed no identifiable cause. In the 6 years since the stroke, while not on methylphenidate there has been no evidence of active central nervous system or systemic vasculitis Comments from the study authors: given its pharmaceutical similarity to amphetamine, the association of methylphenidate with cerebral vasculitis is not unexpected, yet has not been previously reported. Physicians who prescribe methylphenidate for long‐term use should be aware of this potential complication and specifically question patients regarding symptoms of cerebral ischaemia, including headache Supplemental information regarding diagnostic criteria received through personal email correspondence with the authors in September 2013 (Trugman 2013 [pers comm])